Spark Biomedical

Spark Biomedical operates at the intersection of medical devices, therapeutics, digital health, and bioelectronic medicine. Its core differentiation is a non-invasive, wearable delivery model based on Transcutaneous Auricular Neurostimulation, rather than a conventional pharmaceutical intervention or invasive procedure. Sparrow Ascent gives the company a commercial and regulatory anchor in opioid-withdrawal management, while OhmBody, the LUNA trial, and the Neural Tourniquet broaden the platform into women’s health and hemostasis. The company’s 2025 Series A of $15 million, alongside approximately $17.1 million in earlier venture and grant financing, indicates support for a platform strategy rather than a single-product focus. Spark’s clinical collaborations and FDA-cleared Sparrow Ascent distinguish it from earlier-stage neurotechnology developers that remain confined to laboratory research. The company’s competitive risk is therefore concentrated in regulatory execution, reimbursement, clinical validation, and the ability to convert research applications into repeatable commercial products.

Spark Biomedical’s growth trajectory shows a transition from early research funding to a broader clinical and commercial platform. Founded in 2018, the company recorded a $16,234,159 Venture Round on May 12, 2023 and an additional $1,150,000 grant on Aug 29, 2023. The $15 million Series A led by WAVE Ventures on Apr 29, 2025 was the clearest financing inflection point, bringing total recorded funding to $33,058,034 when grants are included. Product expansion has followed the financing: Sparrow Ascent supports opioid-withdrawal management, Health Canada licensed the device in 2025, and OhmBody launched on Sep 3, 2025 for menstrual support. Clinical development then widened into heavy menstrual bleeding, alcohol withdrawal, stress, and hemostasis. The company remains in the 11-to-50 employee range, so public evidence of headcount acceleration is limited. The 2026 appointment of Anja Krammer as CEO suggests a push toward clinical and commercial scale, while the platelet-function study and military-health research activity indicate continued investment in new indications rather than simple geographic expansion.